Break Through Cancer
Radical Collaboration
We can prevent ovarian cancer. Women deserve the option. | Opinion August 13, 2026 | USA Today Dr. Joseph Sakran and Dr. Rebecca Stone Cancer prevention opportunities are rare. When one presents itself safely during an operation a patient is already having, we have a responsibility to consider it. Read the full story on USA Today...
Fallopian tube removal may lower ovarian cancer risk August 10, 2026 | Good Morning America ABC News' Rhiannon Ally and chief medical correspondent Dr. Tara Narula report on a procedure that may reduce ovarian cancer risk by up to 80%. Watch the feature here...
The Lustgarten Foundation and Break Through Cancer Announce New Clinical Trial Evaluating KRAS-targeted Immunotherapy Strategy for Pancreatic Cancer Newly recruiting Phase 1 study will evaluate a next-generation KRAS-targeted immunotherapy, revealing how pancreatic tumor microenvironment shapes treatment response News Release For Immediate Release Media Contact: Alexas Santiago asantiago@lustgarten.org UNIONDALE, New York, — The Lustgarten Foundation and Break Through Cancer today announced the launch of a new Phase 1 clinical trial evaluating a next-generation KRAS-targeted lymph-node stimulating immunotherapy strategy for pancreatic cancer. The study is now recruiting patients with pancreatic ductal adenocarcinoma (PDAC), representing a significant milestone for the organizations' Demystifying Pancreatic......
Most ‘Ovarian Cancer’ Isn’t. And That Fact Can Save Lives. The vast majority of cases begin in the fallopian tubes — and removing them can reduce the risk by nearly 80 percent. July 28, 2026 | Gina Kolata Kira Wynn will do almost anything to avoid ovarian cancer, which killed her mother. “My mom thought she’d pulled a muscle in her side,” Ms. Wynn said. Her mother’s doctor, she added, “told her to do physical therapy.” As is often the case with ovarian cancer, Ms. Wynn’s mother’s disease was already at an advanced stage when she was diagnosed. She......
Breaking Through Pancreatic Cancer with Revolution Medicines For decades, RAS mutations drove more than 90% of pancreatic tumors with no viable therapeutic target. That is now changing. Break Through Cancer's Conquering KRAS in Pancreatic Cancer TeamLab has spent years generating deep molecular data on advanced pancreatic cancer in the laboratory and through a first-of-its-kind clinical trial assessing daraxonrasib – an investigational multi-selective RAS(ON) inhibitor. The TeamLab's clinical trial studies paired pre- and on-treatment biopsies and blood samples to understand how tumors respond, adapt, and resist at the molecular level. In this conversation, Mark Goldsmith, MD, PhD, Chief Executive Officer of......
Break Through Cancer and the Lustgarten Foundation Launch New Pancreatic Cancer Initiative July 02, 2026 | The ASCO Post Staff At a pivotal moment for pancreatic cancer, Break Through Cancer and the Lustgarten Foundation, with support from the Cinelli Family Foundation, has announced a $16 million investment in the Conquering KRAS for Patients with Pancreatic Cancer TeamLab. Spanning six world-class cancer research institutions, this initiative aims to improve outcomes for one of the deadliest cancers by focusing on KRAS, a gene that is mutated in more than 90% of pancreatic cancer cases. Read More The ASCO Post....
At a Turning Point for RAS-directed Therapies, Break Through Cancer and the Lustgarten Foundation Launch New Pancreatic Cancer Initiative Backed by a $16M investment, this collaborative effort will help define the next generation of combination therapy strategies for pancreatic cancer News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) June 29, 2026 – At a pivotal moment for pancreatic cancer, Break Through Cancer and the Lustgarten Foundation today, with support from the Cinelli Family Foundation, announced a $16 million investment in the Conquering KRAS for Patients with Pancreatic Cancer TeamLab. Spanning six world-class cancer research institutions, this......
How scientists found a weakness in one of the deadliest 'undruggable' cancers May 24, 2026 | Calrolyn Johnson “This is the news we've been waiting for. This is the breakthrough — it's been a long time coming,” said Break Through Cancer President Tyler Jacks, PhD, in a recent Washington Post feature examining the decades-long scientific effort that led to KRAS-targeted therapies for pancreatic cancer. In this new article for The Washington Post, Carolyn Johnson traces the scientific journey behind daraxonrasib, from the early discovery of KRAS as a cancer driver to the clinical results that are reshaping expectations for one......
Radical Collaboration: A Cancer Funder Seeks to Solve the Problem of Siloed Research April 20, 2026 | Paul Karon Back in 2021, I wrote about Break Through Cancer, then a newly launched organization focused on addressing a literally deadly problem: overly siloed, disconnected research on the second-leading cause of death in the U.S. and worldwide. Beyond funding research, Break Through Cancer’s leaders seek to create a more effective way to build and operate research teams that span multiple specialties, labs and institutions — the better to untangle cancer’s toughest challenges and develop better ways to diagnose and treat patients. While collaboration between......
Why some family offices are becoming cancer research's new bankrollers March 13, 2026 | Marcus Baram Family offices are stepping in to fill a widening gap in cancer research funding, deploying billions of dollars of patient capital at a moment when federal cuts threaten to stall laboratories and AI breakthroughs promise to accelerate drug development. Read More at Crain Currency....
Break Through Cancer
101 Rogers Street
Suite 3A
Cambridge, MA 02142
Info@breakthroughcancer.org
1-800-757-9881
Quick Links
Annual Reports
